BLAZE-1 Study
- Home
- BLAZE-1 Study
We are looking for people ages 18 and older with COVID-19 illness to take part in a clinical research study called the BLAZE-1 Study.
Address
Website
Alerts
Be the first to know and let us send you an email when BLAZE-1 Study posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Shortcuts
-
Want your practice to be the top-listed Clinic?
Share
BLAZE-1 Study
As you know, COVID-19 is an illness that causes progressive pulmonary infection and can lead to respiratory failure. While symptoms of the illness can vary from person to person, they typically include cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, and changes in taste or smell. Other less common symptoms include nausea, vomiting, and diarrhea.
The sponsor of this study is Eli Lilly and Company. Researchers are evaluating if a study drug can prevent the progression of COVID-19 illness. We are looking for people ages 18 and older who have mild to moderate symptoms. Potential participants must have their first positive COVID-19 infection confirmation within three days prior to the intravenous infusion of the study drug.
Clinical research studies are crucial to helping find new medication options for different conditions. The BLAZE-1 Study is playing an important role in clinical research work for COVID-19, and you may be able to take part.
